Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a standout company in the medical device industry, with a strong track record of success and innovation across its portfolio of heart valve products. Its recent quarter showed continued growth and strong performance in its transcatheter aortic valve business, and its plans for expanding into new areas like surgical tricuspid valve and left atrial appendage closure devices demonstrate its commitment to sustained growth. With a solid financial outlook, diverse product offerings, and a strong focus on patient access initiatives, Edwards Lifesciences is well-positioned for long-term success in the healthcare market.

Bears say

Edwards Lifesciences is expected to experience healthy growth due to its position as a leader in the structural heart disease market and potential for market expansion through guideline updates and new product launches. Despite a potential delay in the TAVR NCD and risks associated with commercial hiccups and competition, strong revenue guidance for the first quarter of 2026 and the company's solid growth profile make its stock a Buy with a $103 price target based on its strong multiple historically and potential for margin expansion.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.74, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.74, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.